FLORENCE, ITALY AND BOSTON

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational oral SERD with positive topline results Additional data presented at SABCS (December 2021) and ASCO (June 2022) Plan […]

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today…

– Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population – In the overall population, elacestrant reduced risk of progression or death by 30% vs. SoC – In the mESR1 population, […]

– Study met both primary endpoints in patients with ER+/HER2- advanced or mBC – Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC – Elacestrant extended PFS in the overall population and the ESR1 mutation subgroup – Plans for […]